# Humanigen

Source: https://onco.cc/companies/humanigen/  
OnCo record `humanigen` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Humanigen, formerly KaloBios, made lenzilumab, an antibody that neutralises GM-CSF to blunt the cytokine storms of CAR-T therapy and COVID-19, before filing for bankruptcy in 2024.

## Summary

Humanigen developed lenzilumab (KB003), a humanised antibody against granulocyte-macrophage colony-stimulating factor. It was studied to prevent cytokine release syndrome and neurotoxicity in patients receiving axicabtagene ciloleucel for lymphoma, in chronic myelomonocytic leukaemia, and in a large randomised trial in hospitalised COVID-19 patients, where the FDA declined emergency authorisation. The company, once KaloBios Pharmaceuticals, filed for Chapter 11 bankruptcy in January 2024.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: KaloBios Pharmaceuticals; Humanigen, Inc.; NASDAQ:HGEN
- Tags: drug-maker
- HQ: Short Hills, New Jersey
- Type: biotech

## Connected records

- drugs: [Lenzilumab](https://onco.cc/drugs/lenzilumab/)

---
JSON: https://onco.cc/api/v1/entities/humanigen.json